Riskpilot← Back to searchSign inGet full accessIpex AB
ABActiveOrg 5565441135SolnaActivities of holding companies · NACE 6421Est. 19970 employees
Revenue 2024
SEK 3,2M
+37% vs 2023
EBITDA margin
-2877.5%
-72728% vs 2023
Equity ratio
86.8%
Financial strength
Net profit 2024
SEK 1,4B
+237% vs 2023
| Revenue | SEK 3,2M | +37% |
| EBITDA | SEK -91,8M | -72728% |
| Net profit | SEK 1,4B | +237% |
| Total assets | SEK 17,2B | +18% |
| Equity | SEK 15B | +10% |
| Employees | 0 | — |
Legal name
Ipex AB
Org number
5565441135
Legal form
Aktiebolag
NACE code
6421 · Activities of holding companies
Founded
4 juli 1997
Share capital
SEK 143 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall tillverka och försälja läkemedel, kemiska produkter, naturmedel och medicinska utensilier samt förvalta aktier ävensom idka därmed förenlig verksamhet.
Address
Solna
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 148 204 | 148 694 | 138 486 | 2 079 | 5 310 | −23 | 2 336 | 3 189 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −35 423 | 5 732 | −8 374 | 9 091 | −575 | −38 042 | 848 | −102 | −126 | −91 763 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −35 423 | 5 732 | −8 374 | 9 091 | −575 | −38 042 | 848 | −102 | −126 | −91 763 |
| Net financials | 662 408 | 3 119 126 | −209 906 | 83 158 | 726 997 | 2 342 701 | −227 751 | −155 106 | −1 250 024 | 1 450 934 |
| Profit before tax | 1 383 513 | 4 430 094 | −110 350 | 172 543 | 448 246 | 2 206 473 | −233 675 | 24 734 | −1 039 723 | 1 423 848 |
| Tax | −95 | −0 | −3 650 | −5 561 | −0 | −4 970 | 4 399 | 152 | 14 510 | −19 874 |
| Net profit | 1 383 418 | 4 430 094 | −114 000 | 166 982 | 448 246 | 2 201 503 | −229 276 | 24 886 | −1 025 213 | 1 403 974 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 28 984 124 | 33 992 051 | 25 089 764 | 28 630 640 | 29 313 446 | 15 199 276 | 14 956 169 | 15 769 853 | 14 599 095 | 17 244 885 |
| Equity | 2 164 257 | 6 594 352 | 4 698 115 | 9 586 684 | 10 034 931 | 14 251 635 | 14 022 360 | 14 639 862 | 13 578 344 | 14 977 057 |
| Long-term debt | 26 685 652 | 27 355 605 | 20 337 811 | 18 971 320 | 19 256 843 | 932 500 | 932 782 | 932 950 | 955 406 | 965 225 |
| Short-term debt | 134 215 | 42 094 | 53 838 | 72 636 | 21 672 | 10 170 | 1 028 | 197 041 | 65 345 | 1 302 603 |
| Total debt | 26 819 867 | 27 397 699 | 20 391 649 | 19 043 956 | 19 278 515 | 942 670 | 933 810 | 1 129 991 | 1 020 751 | 2 267 828 |
EBITDA margin
-2877.5%
This company
15.8%
Market median
-18312% vs market
20152024
Equity ratio
86.8%
This company
38.2%
Market median
+127% vs market
20152024
Return on equity
9.4%
This company
18.4%
Market median
-49% vs market
20152024
Net profit margin
44025.5%
This company
8.1%
Market median
+543425% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.15×
This company
0.62×
Market median
+76% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AP Chief Auditor | Chief Auditor | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2021 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Meda Aktiebolag | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
UTAH ACQUISITION SUB INC.Bgp Products ABMeda Aktiebolag
Ipex AB (this company)Med Pharma S.A.R.lMeda Pharma Servicios S. De Rl De C.vMylan Philipines IncMeda Pharmaceuticals Hong Kong Ltd.Laboratàrios Delta, Lda.Meda Pharmaceuticals Middle East & Africa Fz LlcMeda Pharma S.A./N.V.Meda Pharma SiaMedicine Meda Pharmaceutical Information ConsultMeda Pharma Spol S.R.O.Meda Pharma Ilac San.I Ve Tic. LtdMeda Pharma S.R.O.Laboratorios Delta SaMeda Pharmacentials Ltd.Meda Pharma LlcMeda Pharma South Africa (Pty) LtdMeda Pharma Produtos Farmac?Uticals S.A.Meda Pharmaceuticals Switzerland GmbhMeda Pharma S.L.Meda Pharma GmbhMeda Pharma S.A.R.lMeda Holding SasMeda Healthcare Sdn. Bhd.Mylan Österreich GmbhMED PHARMA S.A.R.LMEDA HEALTHCARE SDN. BHD.MEDA PHARMA S.L.MEDA PHARMACEUTICALS HONG KONG LTD.MEDA PHARMA S.A./N.V.MEDA PHARMA SOUTH AFRICA (PTY) LTDLABORATORIOS DELTA SAMEDA PHARMA LLCMYLAN PHILIPINES INCMYLAN ÖSTERREICH GMBHMEDA PHARMA SERVICIOS S. DE RL DE C.VMEDA PHARMACEUTICALS SWITZERLAND GMBHBoard members of Ipex AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Arne Pontus Pålsson | Chief Auditor | 0 companies |
| Lars Henrik Andreas Rejnus | Chairman | 0 companies |
| Bernard Christiaan Spoelstra | Chairman | 0 companies |
| Caroline Rebecca Louise Dixon | Board of Directors | 0 companies |
| Jenny Friberg | Board of Directors | 0 companies |
| Jan-Christer Stefan Engryd | Board of Directors | 0 companies |
| Jose Javier Cotarelo | Board of Directors | 0 companies |
| Vidar Sie | Deputy Board Member | 0 companies |